Cell-Based Therapies for Degenerative Disc Diseases
Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. H...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lv, Feng-Juan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2016 ; number:3 ; pages:182-188 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1053/j.oto.2016.06.008 |
|---|
| Katalog-ID: |
ELV040169863 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV040169863 | ||
| 003 | DE-627 | ||
| 005 | 20230625231058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.oto.2016.06.008 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016018000024.pica |
| 035 | |a (DE-627)ELV040169863 | ||
| 035 | |a (ELSEVIER)S1048-6666(16)30020-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.63 |2 bkl | ||
| 084 | |a 44.69 |2 bkl | ||
| 100 | 1 | |a Lv, Feng-Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cell-Based Therapies for Degenerative Disc Diseases |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. | ||
| 520 | |a Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. | ||
| 650 | 7 | |a degenerative disc diseases |2 Elsevier | |
| 650 | 7 | |a intervertebral disc |2 Elsevier | |
| 650 | 7 | |a low back pain |2 Elsevier | |
| 650 | 7 | |a mesenchymal stem cells |2 Elsevier | |
| 650 | 7 | |a cell therapies |2 Elsevier | |
| 700 | 1 | |a Leung, Victor Y.L. |4 oth | |
| 700 | 1 | |a Cheung, Kenneth M.C. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV026914158 |
| 773 | 1 | 8 | |g volume:26 |g year:2016 |g number:3 |g pages:182-188 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1053/j.oto.2016.06.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_72 | ||
| 912 | |a GBV_ILN_217 | ||
| 912 | |a GBV_ILN_255 | ||
| 912 | |a GBV_ILN_365 | ||
| 912 | |a GBV_ILN_674 | ||
| 936 | b | k | |a 44.63 |j Krankenpflege |q VZ |
| 936 | b | k | |a 44.69 |j Intensivmedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2016 |e 3 |h 182-188 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f j l fjl |
|---|---|
| matchkey_str |
lvfengjuanleungvictorylcheungkennethmc:2016----:elaeteaisodgnrtv |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
44.63 44.69 |
| publishDate |
2016 |
| allfields |
10.1053/j.oto.2016.06.008 doi GBVA2016018000024.pica (DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Lv, Feng-Juan verfasserin aut Cell-Based Therapies for Degenerative Disc Diseases 2016transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier Leung, Victor Y.L. oth Cheung, Kenneth M.C. oth Enthalten in Elsevier Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026914158 volume:26 year:2016 number:3 pages:182-188 extent:7 https://doi.org/10.1053/j.oto.2016.06.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 44.63 Krankenpflege VZ 44.69 Intensivmedizin VZ AR 26 2016 3 182-188 7 045F 610 |
| spelling |
10.1053/j.oto.2016.06.008 doi GBVA2016018000024.pica (DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Lv, Feng-Juan verfasserin aut Cell-Based Therapies for Degenerative Disc Diseases 2016transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier Leung, Victor Y.L. oth Cheung, Kenneth M.C. oth Enthalten in Elsevier Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026914158 volume:26 year:2016 number:3 pages:182-188 extent:7 https://doi.org/10.1053/j.oto.2016.06.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 44.63 Krankenpflege VZ 44.69 Intensivmedizin VZ AR 26 2016 3 182-188 7 045F 610 |
| allfields_unstemmed |
10.1053/j.oto.2016.06.008 doi GBVA2016018000024.pica (DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Lv, Feng-Juan verfasserin aut Cell-Based Therapies for Degenerative Disc Diseases 2016transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier Leung, Victor Y.L. oth Cheung, Kenneth M.C. oth Enthalten in Elsevier Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026914158 volume:26 year:2016 number:3 pages:182-188 extent:7 https://doi.org/10.1053/j.oto.2016.06.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 44.63 Krankenpflege VZ 44.69 Intensivmedizin VZ AR 26 2016 3 182-188 7 045F 610 |
| allfieldsGer |
10.1053/j.oto.2016.06.008 doi GBVA2016018000024.pica (DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Lv, Feng-Juan verfasserin aut Cell-Based Therapies for Degenerative Disc Diseases 2016transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier Leung, Victor Y.L. oth Cheung, Kenneth M.C. oth Enthalten in Elsevier Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026914158 volume:26 year:2016 number:3 pages:182-188 extent:7 https://doi.org/10.1053/j.oto.2016.06.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 44.63 Krankenpflege VZ 44.69 Intensivmedizin VZ AR 26 2016 3 182-188 7 045F 610 |
| allfieldsSound |
10.1053/j.oto.2016.06.008 doi GBVA2016018000024.pica (DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Lv, Feng-Juan verfasserin aut Cell-Based Therapies for Degenerative Disc Diseases 2016transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier Leung, Victor Y.L. oth Cheung, Kenneth M.C. oth Enthalten in Elsevier Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026914158 volume:26 year:2016 number:3 pages:182-188 extent:7 https://doi.org/10.1053/j.oto.2016.06.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 44.63 Krankenpflege VZ 44.69 Intensivmedizin VZ AR 26 2016 3 182-188 7 045F 610 |
| language |
English |
| source |
Enthalten in Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes Amsterdam [u.a.] volume:26 year:2016 number:3 pages:182-188 extent:7 |
| sourceStr |
Enthalten in Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes Amsterdam [u.a.] volume:26 year:2016 number:3 pages:182-188 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Krankenpflege Intensivmedizin |
| institution |
findex.gbv.de |
| topic_facet |
degenerative disc diseases intervertebral disc low back pain mesenchymal stem cells cell therapies |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |
| authorswithroles_txt_mv |
Lv, Feng-Juan @@aut@@ Leung, Victor Y.L. @@oth@@ Cheung, Kenneth M.C. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV026914158 |
| dewey-sort |
3610 |
| id |
ELV040169863 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040169863</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231058.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.oto.2016.06.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040169863</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1048-6666(16)30020-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.63</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.69</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lv, Feng-Juan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cell-Based Therapies for Degenerative Disc Diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">degenerative disc diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">intervertebral disc</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">low back pain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mesenchymal stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cell therapies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leung, Victor Y.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Kenneth M.C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV026914158</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:182-188</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.oto.2016.06.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_217</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_255</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_365</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_674</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.63</subfield><subfield code="j">Krankenpflege</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.69</subfield><subfield code="j">Intensivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">182-188</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Lv, Feng-Juan |
| spellingShingle |
Lv, Feng-Juan ddc 610 ddc 540 bkl 44.63 bkl 44.69 Elsevier degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Cell-Based Therapies for Degenerative Disc Diseases |
| authorStr |
Lv, Feng-Juan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV026914158 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl Cell-Based Therapies for Degenerative Disc Diseases degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies Elsevier |
| topic |
ddc 610 ddc 540 bkl 44.63 bkl 44.69 Elsevier degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies |
| topic_unstemmed |
ddc 610 ddc 540 bkl 44.63 bkl 44.69 Elsevier degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies |
| topic_browse |
ddc 610 ddc 540 bkl 44.63 bkl 44.69 Elsevier degenerative disc diseases Elsevier intervertebral disc Elsevier low back pain Elsevier mesenchymal stem cells Elsevier cell therapies |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
v y l vy vyl k m c km kmc |
| hierarchy_parent_title |
Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |
| hierarchy_parent_id |
ELV026914158 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV026914158 |
| title |
Cell-Based Therapies for Degenerative Disc Diseases |
| ctrlnum |
(DE-627)ELV040169863 (ELSEVIER)S1048-6666(16)30020-9 |
| title_full |
Cell-Based Therapies for Degenerative Disc Diseases |
| author_sort |
Lv, Feng-Juan |
| journal |
Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |
| journalStr |
Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
182 |
| author_browse |
Lv, Feng-Juan |
| container_volume |
26 |
| physical |
7 |
| class |
610 610 DE-600 540 VZ 610 VZ 44.63 bkl 44.69 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lv, Feng-Juan |
| doi_str_mv |
10.1053/j.oto.2016.06.008 |
| dewey-full |
610 540 |
| title_sort |
cell-based therapies for degenerative disc diseases |
| title_auth |
Cell-Based Therapies for Degenerative Disc Diseases |
| abstract |
Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. |
| abstractGer |
Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. |
| abstract_unstemmed |
Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_21 GBV_ILN_72 GBV_ILN_217 GBV_ILN_255 GBV_ILN_365 GBV_ILN_674 |
| container_issue |
3 |
| title_short |
Cell-Based Therapies for Degenerative Disc Diseases |
| url |
https://doi.org/10.1053/j.oto.2016.06.008 |
| remote_bool |
true |
| author2 |
Leung, Victor Y.L. Cheung, Kenneth M.C. |
| author2Str |
Leung, Victor Y.L. Cheung, Kenneth M.C. |
| ppnlink |
ELV026914158 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1053/j.oto.2016.06.008 |
| up_date |
2024-07-06T16:49:49.700Z |
| _version_ |
1803849133933461504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040169863</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231058.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.oto.2016.06.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040169863</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1048-6666(16)30020-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.63</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.69</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lv, Feng-Juan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cell-Based Therapies for Degenerative Disc Diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intervertebral discs degeneration are responsible for most of cases of low back pain, which affects millions of people worldwide. Current clinical therapies for degenerative disc diseases involve medications or physiotherapy for mild to moderate degeneration, and surgeries for severe degeneration. However, current treatments aim to remove symptoms sometimes at the cost of mobility instead of restoring the biological function. Future therapy for disc repair is in development by biological strategies, including protein or growth factor injections, gene therapy or cell therapy approaches. Cell-based therapies provide the greatest hope, as it is a continuous source of cells and cytokine production, and the safety is superior compared to gene therapy. The choice of cell source includes chondrocytes, disc cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells. Results of several clinical trials suggest that mesenchymal stem cells are the best choice of cell source for intervertebral discs regeneration. The remaining concern is that the harsh environment of the degenerated disc may have effect on the engraftment and differentiation of implanted cells. The timing of cell implantation may also have effect on the degree of disc regeneration, which may require an earlier intervention at mild to moderate level of disc degeneration to achieve satisfactory surgical outcome.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">degenerative disc diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">intervertebral disc</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">low back pain</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mesenchymal stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cell therapies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leung, Victor Y.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Kenneth M.C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">Influence of ionic charge placement on performance of poly(ethylene glycol)-based sulfonated polyurethanes</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV026914158</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:182-188</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.oto.2016.06.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_217</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_255</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_365</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_674</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.63</subfield><subfield code="j">Krankenpflege</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.69</subfield><subfield code="j">Intensivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">182-188</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.398514 |